Download PDF
Deutsche Zeitschrift für Onkologie 2010; 42(2): 60-65
DOI: 10.1055/s-0029-1242612
Forschung
© Karl F. Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Komplementärmedizin (KAM) in der gynäkologischen Onkologie

Karsten Münstedt, Igor Hrgovic
Further Information

Publication History

Publication Date:
30 June 2010 (online)

    Permissions and Reprints

Zusammenfassung

Tumoren aus dem Bereich der gynäkologischen Onkologie haben in der Regel eine günstige Prognose, da sie meist in Frühstadien erkannt werden. Dennoch nutzen gynäkologisch-onkologische Patientinnen, insbesondere Brustkrebspatientinnen, die Möglichkeiten der komplementären und alternativen Medizin. Derzeit erfolgt diese Behandlung weitgehend ohne einen rationalen Hintergrund. Inzwischen liegen aber einzelne situationsbezogene und entitätsspezifische Studien vor, die eine Beratung auf rationaler Ebene ermöglichen. Diese sollten im Hinblick auf die Wirksamkeit und die Sicherheit stärker berücksichtigt werden.

Summary

Carcinomas from the field of gynaecologic oncology are generally associated with a favourable prognosis as most of them can be detected quite early. In spite of these favourable chances many patients, especially breast cancer patients, use the treatment possibilities of complementary and alternative medicine. However, the current treatment recommendations mostly are not based on a rational background. Meanwhile there are several studies which allow a reasonable consultation on the topic. These should be recognised.

Schlüsselwörter

Gynäkologische Tumoren - Komplementärmedizin (KAM) - Onkologie

Keywords

gynaecologic carcinomas - complementary medicine (CAM) - oncology

Literatur

  • 01 Beuth J, Ost B, Pakdaman A, Rethfeld E, Bock P R, Hanisch J, Schneider B. Impact of complementary oral enzyme application on the postoperative treatment results of breast cancer patients - results of an epidemiological multicentre retrolective cohort study.  Cancer Chemother Pharmacol. 2001;  47 Suppl.: S45–54
    Google Scholar
  • 02 Bohm S, Battista Spatti G, Di Re F, Oriana S, Pilotti S, Tedeschi M, Tognella S, Zunino F. A feasibility study of cisplatin administration with low-volume hydration and glutathione protection in the treatment of ovarian carcinoma.  Anticancer Res. 1991;  11 1613-1616
    Google Scholar
  • 03 Bardy J, Slevin N J, Mais K L, Molassiotis A. A systematic review of honey uses and its potential value within oncology care.  J Clin Nurs. 2008;  17 2604-2623
    Google Scholar
  • 04 Chan M M, Soprano K J, Weinstein K, Fong D. Epigallocatechin-3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility.  J Cell Physiol. 2006;  207 389-396
    Google Scholar
  • 05 Di Re F, Bohm S, Oriana S, Spatti G B, Zunino F. Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer.  Cancer Chemother Pharmacol. 1990;  25 355-360
    Google Scholar
  • 06 Duskova M, Wald M. Orally administered proteases in aesthetic surgery.  Aesthetic Plast Surg. 1999;  23 41-44
    Google Scholar
  • 07 Ernst E, Schmidt K, Baum M. Complementary/Alternative therapies for the treatment of breast cancer. A systematic review of randomized clinical trials and a critique of current terminology.  Breast J. 2006;  12 526-530
    Google Scholar
  • 08 Fujitani T. Influence of proteolytic enzymes on permeation of antibiotics into maxillary sinus membrane of patients with chronic sinusitis.  Otorhinic Clinic. 1973;  66 557-565
    Google Scholar
  • 09 Frenkel G D, Caffrey P B. A prevention strategy for circumventing drug resistance in cancer chemotherapy.  Curr Pharm Des. 2001;  7 1595-1614
    Google Scholar
  • 10 García-Closas R, Castellsagué X, Bosch X, González C A. The role of diet and nutrition in cervical carcinogenesis. a review of recent evidence.  Int J Cancer. 2005;  117 629-637
    CrossrefPubMedGoogle Scholar
  • 11 Goodwin P J, Ennis M, Pritchard K I, Koo J, Trudeau M E, Hood N. Diet and breast cancer. evidence that extremes in diet are associated with poor survival.  J Clin Oncol. 2003;  21 2500-2507
    CrossrefPubMedGoogle Scholar
  • 12 Hernandez-Reif M, Ironson G, Field T, Hurley J, Katz G, Diego M, Weiss S, Fletcher M A, Schanberg S, Kuhn C, Burman I. Breast cancer patients have improved immune and neuroendocrine functions following massage therapy.  J Psychosom Res. 2004;  57 45-52
    CrossrefPubMedGoogle Scholar
  • 13 Horneber M A, Bueschel G, Huber R, Linde K, Rostock M. Mistletoe therapy in oncology. Cochrane Database Syst Rev; 2008 (2) CD003297
    PubMedGoogle Scholar
  • 14 Howat R C L, Lewis G D. The effect of bromelain therapy on episiotomy wounds. A double-blind controlled clinical trial.  Obstet Gynaecol. 1972;  77 365-368
    PubMedGoogle Scholar
  • 15 Grossarth-Maticek R, Ziegler R. Prospective controlled cohort studies on long-term therapy of ovairian cancer patients with mistletoe (Viscum album L.) extracts iscador.  Arzneimittelforschung. 2007;  57(10) 665-78
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Koyama A, Mori J, Tokuda H, Waku M, Anno H, Katayama T, Murakami K, Komatsu H, Hirata M, Arai T et al.. Augmentation by serrapeptase of tissue permeation by cefotiam.  Jpn J Antibiot. 1986;  39 761-771
    PubMedGoogle Scholar
  • 17 Labourey J L. Physical activity in the management of cancer-related fatigue induced by oncological treatments.  Ann Readapt Med Phys. 2007;  50 445-454
    PubMedGoogle Scholar
  • 18 Larsson S C, Wolk A. Tea consumption and ovarian cancer risk in a population-based cohort.  Arch Intern Med. 2005;  165 2683-2686
    CrossrefPubMedGoogle Scholar
  • 19 Lesperance M L, Olivotto I A, Forde N, Zhao Y, Speers C, Foster H, Tsao M, MacPherson N, Hoffer A. Mega-dose vitamins and minerals in the treatment of non-metastatic breast cancer. an historical cohort study.  Breast Cancer Res Treat. 2002;  76 137-143
    CrossrefPubMedGoogle Scholar
  • 20 Li Z, Carrier L, Belame A, Thiyagarajah A, Salvo V A, Burow M E, Rowan B G. Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis.  Breast Cancer Res Treat. 2008;  118 33-43
    CrossrefPubMedGoogle Scholar
  • 21 Li Z, Carrier L, Rowan B G. Methylseleninic acid synergizes with tamoxifen to induce caspase-mediated apoptosis in breast cancer cells.  Mol Cancer Ther. 2008;  7 3056-3063
    CrossrefPubMedGoogle Scholar
  • 22 Lissoni P, Tancini G, Paolorossi F, Mandala M, Ardizzoia A, Malugani F, Giani L, Barni S. Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin. a phase II study.  J Pineal Res. 1999;  26 169-173
    CrossrefPubMedGoogle Scholar
  • 23 Locatelli M C, D'Antona A, Labianca R, Vinci M, Tedeschi M, Carcione R, Corbo A, Venturino P, Luporini G. A phase II study of combination chemotherapy in advanced ovarian carcinoma with cisplatin and cyclophosphamide plus reduced glutathione as potential protective agent against cisplatin toxicity.  Tumori. 1993;  79 37-39
    PubMedGoogle Scholar
  • 24 Moolenaar M, Poorter R L, van der Toorn P P, Lenderink A W, Poortmans P, Egberts A C. The effect of honey compared to conventional treatment on healing of radiotherapy-induced skin toxicity in breast cancer patients.  Acta Oncologica. 2006;  45 623-624
    CrossrefPubMedGoogle Scholar
  • 25 Münstedt K Hrsg.. Ratgeber unkonventionelle Krebstherapien. 2. Aufl. Landsberg: Ecomed; 2005
    Google Scholar
  • 26 Nagel G, Hoyer H, Katenkamp D. Use of complementary and alternative medicine by patients with breast cancer. observations from a health-care survey.  Support Care Cancer. 2004;  12 789-796
    CrossrefPubMedGoogle Scholar
  • 27 Nagle C M, Purdie D M, Webb P M, Green A, Harvey P W, Bain C J. Dietary influences on survival after ovarian cancer.  Int J Cancer. 2003;  106 264-269
    CrossrefPubMedGoogle Scholar
  • 28 Oh W K, Kantoff P W, Weinberg V, Jones G, Rini B I, Derynck M K, Bok R, Smith M R, Bubley G J, Rosen R T, DiPaola R S, Small E J. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.  J Clin Oncol. 2004;  22 3705-3712
    CrossrefPubMedGoogle Scholar
  • 29 Sartippour M R, Pietras R, Marquez-Garban D C, Chen H W, Heber D, Henning S M, Sartippour G, Zhang L, Lu M, Weinberg O, Rao J Y, Brooks M N. The combination of green tea and tamoxifen is effective against breast cancer.  Carcinogenesis. 2006;  27 2424-2433
    CrossrefPubMedGoogle Scholar
  • 30 Seely D, Oneschuk D. Interactions of natural health products with biomedical cancer treatments.  Curr Oncol. 2008;  15 Suppl 2:s109.es81–10.es86
    PubMedGoogle Scholar
  • 31 Shah Y M, Al-Dhaheri M, Dong Y, Ip C, Jones F E, Rowan B G. Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells.  Mol Cancer Ther. 2005;  4 1239-1249
    CrossrefPubMedGoogle Scholar
  • 32 Shannon J, Thomas D B, Ray R M, Kestin M, Koetsawang A, Koetsawang S, Chitnarong K, Kiviat N, Kuypers J. Dietary risk factors for invasive and in-situ cervical carcinomas in Bangkok, Thailand.  Cancer Causes Control. 2002;  13 691-699
    CrossrefPubMedGoogle Scholar
  • 33 Sieja K, Talerczyk M. Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy.  Gynecol Oncol. 2004;  93 320-327
    CrossrefPubMedGoogle Scholar
  • 34 Seely D, Mills E J, Wu P, Verma S, Guyatt G H. The effects of green tea consumption on incidence of breast cancer and recurrence of breast cancer. a systematic review and meta-analysis.  Integr Cancer Ther. 2005;  4 144-155
    CrossrefPubMedGoogle Scholar
  • 35 Semiglazov V F. Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial.  Anticancer Res. 2006;  26 1519-1529
    PubMedGoogle Scholar
  • 36 Shord S S, Shah K, Lukose A. Drug-botanical interactions. a review of the laboratory, animal, and human data for 8 common botanicals.  Integr Cancer Ther. 2009;  8 208-227
    PubMedGoogle Scholar
  • 37 Smyth J F, Bowman A, Perren T, Wilkinson P, Prescott R J, Quinn K J, Tedeschi M. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin. results of a double-blind, randomised trial.  Ann Oncol. 1997;  8 569-563
    CrossrefPubMedGoogle Scholar
  • 38 Vadgama J V, Wu Y, Shen D, Hsia S, Block J. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells.  Anticancer Res. 2000;  20 1391-1414
    PubMedGoogle Scholar
  • 39 Verhoef M J, Balneaves L G, Boon H S, Vroegindewey A. Reasons for and characteristics associated with complementary and alternative medicine use among adult cancer patients. a systematic review.  Integr Cancer Ther. 2005;  4 274-286
    CrossrefPubMedGoogle Scholar
  • 40 Willich S N, Girke M, Hoppe J-D, Kiene H, Klitzsch W, Matthiessen P F, Meister P, Ollenschläger Günter, Heimpel H. Schulmedizin und Komplementärmedizin: Verständnis und Zusammenarbeit müssen vertieft werden.  Dtsch Ärztebl. 2004;  101 A-1314-1319
    PubMedGoogle Scholar
  • 41 van der Zee J, van Rhoon G C. Cervical cancer. radiotherapy and hyperthermia.  Int J Hyperthermia. 2006;  22 229-234
    CrossrefPubMedGoogle Scholar

Korrespondenzadresse

Prof. Dr. med. Karsten Münstedt

Universitätsfrauenklinik Gießen

Klinikstrasse 32

35392 Gießen

Phone: +49 (641) 99 45200

Fax: +49 (641) 99 45139

Email: karsten.muenstedt@gyn.med.uni-giessen.de